Safety Study of GCS-100 to Treat Chronic Kidney Disease

Chronic Kidney Disease Clinical Trial

Official title:

A Phase 1 Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01717248
• Other study ID #: GCS-100-CS-4001
• Status: Completed
• Phase: Phase 1
• First received: October 26, 2012
• Last updated: June 19, 2013
• Start date: January 2013
• Est. completion date: June 2013

Study information

• Verified date: June 2013
• Source: La Jolla Pharmaceutical Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Subject is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.

2. Subject is male or female, aged >=18 and <= 75. Patients older than 75 y/o will be included at the request of the investigator and at the discretion of the Medical Monitor .

3. Adult patients with chronic kidney disease for longer than 12 months and stable in the opinion of the investigator for the past 3 months 4. Systolic blood pressure <=160 mm Hg and >= 90 mm Hg on 2 readings. Diastolic blood pressure <= 100 mm Hg and >= 40 mm Hg on 2 readings during at least one of the screening visits.

5. Subject is willing to practice birth control. 6. Subject is willing and able to comply with all protocol requirements. 7. Subject has a measureable level of galectin-3 concentration in plasma at any time prior to entry.

8. Subject has a glomerular filtration rate between 15-45 mL/min/1.73 m2 determined using the CKD-EPI equation (see section 3.6.1) 9. Subject's has clinical laboratory values of:

1. Hemoglobin =9 g/dL

2. Total bilirubin = 1.5 X Institutional Upper Limit of Normal (IULN)

3. AST and/or ALT = 2.5 X the upper limit of normal 10. Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least 1 year) and male subjects with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the study period.

Exclusion Criteria:

1. Subjects who have had treatment with an experimental (unlicensed) drug within 4 weeks or = 5 half-lives prior to treatment with GCS 100.

2. Subjects with kidney disease due to systemic lupus erythematosus (regardless of whether active or in remission), any form of vasculitis (regardless of whether active or in remission), IgA nephropathy, multiple myeloma, polycystic kidney disease, untreated obstructed nephropathy or any other causes that in the opinion of the investigator may put the subject at an increased risk

3. Subject is expected to start renal replacement therapy of any kind within 6 months after enrollment

4. Subjects with previous solid organ transplant

5. Subject is undergoing treatment with immunosuppression agents except for topical agents or inhaled steroids when conditions are chronic and stable.

6. Subject with know history of cancer within the past 5 years prior to enrollment excluding non-melanoma skin cancer that is not being actively treated

7. Subject has a known history of human immunodeficiency virus infection, active hepatitis C, active hepatitis B, or prior history of infection with hepatitis B (HBcAb positive). Medical Monitor may approve if adequate hepatic function has been documented for patients without evidence of cirrhosis for subjects with HCV or prior history of hepatitis B, including, but not limited to liver biopsy.

8. Subject has a clinically relevant active infection and/or a serious co-morbid medical condition such as recent myocardial infarction (within the last 6 months), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.

9. Subject had major surgery within 4 weeks prior to Study Day 1.

10. If female, subject is pregnant or breastfeeding.

11. Subject has a concomitant disease or condition, including laboratory abnormalities, which in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• GCS-100
GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).

Locations

Country	Name	City	State
United States	Denver Nephrologists, PC	Denver	Colorado
United States	California Institue of Renal Research	La Mesa	California
United States	Renal Associates PA / Research Division	San Antonio	Texas
United States	Southwest Clinical Research Institute	Tempe	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
La Jolla Pharmaceutical Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of Safety	Assess overall safety of rising dose of GCS-100 in CKD patients	Ongoing	Yes